The Perception of Contraceptive Practice Among Female Patients Treated With Isotretinoin in Saudi Arabia
- PMID: 39411596
- PMCID: PMC11474520
- DOI: 10.7759/cureus.69390
The Perception of Contraceptive Practice Among Female Patients Treated With Isotretinoin in Saudi Arabia
Abstract
Background Practicing and following a Pregnancy Prevention Program (PPP) is crucial to prevent isotretinoin-induced teratogenicity. Our study aims to assess the current practice of dermatologists about PPP when prescribing oral isotretinoin and the compliance of the patients toward contraceptive methods. Methods The research used a cross-sectional design and utilized a probability sampling method in Saudi Arabia. An online self-administered questionnaire was used to collect data that included female participants who were previously treated/being treated with isotretinoin for acne. Data was analyzed using SPSS (IBM Inc., Armonk, New York). Results Our study examined 359 female patients receiving isotretinoin treatment. Isotretinoin was primarily used for severe nodular forms of acne resistant to regular treatment 229 (63.8%). Regarding awareness, 326 (90.8%) were familiar with isotretinoin's teratogenic effects, and 112 (31.2%) were familiar with the Saudi Food and Drug Authority's Pregnancy Prevention Program. Physicians were among the most prevalent information sources 254 (71%). In terms of isotretinoin usage, 227 (63.2%) had one course. Regarding contraceptive practice, 167 (46.5%) were informed about the necessity of a negative pregnancy test before starting treatment, and 29 (50.9%) of those who received more than two courses had good awareness. Conclusion The study identified a notable awareness gap among the participants, as over two-thirds demonstrated a poor awareness level regarding isotretinoin. A significant proportion of participants were informed about the importance of contraceptive practices, including the necessity of a negative pregnancy test before, during, and after treatment.
Keywords: contraception; female; isotretinoin; perception; saudi arabia; teratogenicity.
Copyright © 2024, Almarri et al.
Conflict of interest statement
Human subjects: Consent was obtained or waived by all participants in this study. Deanship of Scientific Research of King Faisal University issued approval KFU-REC-2023-MAY-ETHICS828. The Research Ethics Committee of King Faisal University grants its ethical approval to the protocol. The researchers are held accountable for the storage, retention, and security of original data obtained from projects. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures
Similar articles
-
Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients.Saudi Pharm J. 2021 Jun;29(6):527-532. doi: 10.1016/j.jsps.2021.04.013. Epub 2021 Apr 23. Saudi Pharm J. 2021. PMID: 34194259 Free PMC article.
-
Knowledge on the Use of Isotretinoin and Its Side Effects and Awareness towards Saudi FDA-Pregnancy Prevention Program among the Female Acne Patients: A Northern Saudi Study.Medicina (Kaunas). 2022 Nov 7;58(11):1609. doi: 10.3390/medicina58111609. Medicina (Kaunas). 2022. PMID: 36363566 Free PMC article.
-
Awareness on Teratogenic Effects of Isotretinoin and Compliance with Precautionary Measures among Women of Childbearing Age in Makkah Province, Saudi Arabia.Obstet Gynecol Int. 2021 Apr 10;2021:9966300. doi: 10.1155/2021/9966300. eCollection 2021. Obstet Gynecol Int. 2021. PMID: 33936210 Free PMC article.
-
A comparative review of the isotretinoin pregnancy risk management programs across four continents.Int J Dermatol. 2018 Sep;57(9):1035-1046. doi: 10.1111/ijd.13950. Epub 2018 Mar 6. Int J Dermatol. 2018. PMID: 29508918 Review.
-
Contraceptive counseling for iPLEDGE and its burden on dermatologists.Arch Dermatol Res. 2024 May 28;316(6):287. doi: 10.1007/s00403-024-03070-5. Arch Dermatol Res. 2024. PMID: 38805059 Review.
Cited by
-
Compliance with the European Pregnancy Prevention Programme in Isotretinoin Treatment: Safety Outcomes and Dose-Related Correlations.J Clin Med. 2025 May 16;14(10):3497. doi: 10.3390/jcm14103497. J Clin Med. 2025. PMID: 40429495 Free PMC article.
References
-
- Public understanding and awareness of isotretinoin use and safety in Al Ahsa, eastern Saudi Arabia. Younis NS, Al-Harbi NY. Ther Innov Regul Sci. 2019;53:618–622. - PubMed
-
- Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium. Lelubre M, Hamdani J, Senterre C, et al. Pharmacoepidemiol Drug Saf. 2018;27:668–673. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous